benzyl 2,3,4-tri-O-benzyl-α-D-mannopyranuronic acid | 858352-14-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: benzyl 2,3,4-tri-O-benzyl-α-D-mannopyranuronic acid
• 英文别名: (2S,3S,4S,5S,6S)-3,4,5,6-tetrakis(phenylmethoxy)oxane-2-carboxylic acid
• CAS: 858352-14-4
• 化学式: C₃₄H₃₄O₇
• 分子量: 554.64
• InChiKey: DZTFRMXHQHBJOQ-JOBLXHLTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  41
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  83.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  benzyl 2,3,4-tri-O-benzyl-α-D-mannopyranuronic acid 在 正丁基锂 、 18-冠醚-6 、 zinc borohydride 、 potassium carbonate 、 臭氧 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 正己烷 、 二氯甲烷 、 甲苯 为溶剂， 反应 1.75h， 生成 benzyl 2,3,4-tri-O-benzyl-α-D-glycero-D-manno-heptopyranoside
  参考文献：
  名称：

  糖膦酸酯在制备高级碳单糖中的应用

  摘要：

  摘要糖衍生的膦酸酯[Sug-C（O）CH2P（O）（OMe）2]与糖醛（Sug'-CHO）的反应提供了通式为Sug-C（O）CH = CH-Sug的高级烯酮具有双键的反式构型。膦酸酯方法优于先前使用的膦烷方法[Sug-C（O）CH = PPh3 + Sug'-CHO]，因为糖膦酸酯可以以更高的产率制备并且比相应的膦烷亲核得多。用硼氢化锌将糖烯酮还原为合适的烯丙醇；当羰基位于糖环的α-位置时，此过程的立体选择性> 97：3（D-甘油异构体占主导）。CD光谱法用于确定高级糖烯丙基醇的构型。

  DOI：

  10.1080/07328309908544046
• 作为产物：
  描述：

  (2S,3S,4S,5S,6R)-2-benzyloxy-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol 在 吡啶 、 4-二甲氨基吡啶 、 potassium dichromate 、 硫酸 、 氢溴酸 、 sodium hydride 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 21.4h， 生成 benzyl 2,3,4-tri-O-benzyl-α-D-mannopyranuronic acid
  参考文献：
  名称：

  Glycosylated Platinum(IV) Complexes as Substrates for Glucose Transporters (GLUTs) and Organic Cation Transporters (OCTs) Exhibited Cancer Targeting and Human Serum Albumin Binding Properties for Drug Delivery

  摘要：

  Glycosylated platinum(IV) complexes were synthesized as substrates for GLUTs and OCTs for the first time, and the cytotoxicity and detailed mechanism were determined in vitro and in vivo. Galactoside Pt(IV), glucoside Pt(IV), and mannoside Pt(W) were highly cytotoxic and showed specific cancer-targeting properties in vitro and in vivo. Glycosylated platinum(W) complexes 5, 6, 7, and 8 (IC50 0.24-3.97 mu M) had better antitumor activity of nearly 166-fold higher than the positive controls cisplatin (1a), oxaliplatin (3a), and satraplatin (5a). The presence of a hexadecanoic chain allowed binding with human serum albumin (HSA) for drug delivery, which not only enhanced the stability of the inert platinum(IV) prodrugs but also decreased their reduction by reductants present in human whole blood. Their preferential accumulation in cancer cells compared to noncancerous cells (293T and 3T3 cells) suggested that they were potentially safe for clinical therapeutic use.

  DOI：

  10.1021/acs.jmedchem.7b00433

文献信息

• Efficient Chemoenzymatic Synthesis of ADP-<scp>d</scp>-<i>g</i><i>lycero</i>-β-<scp>d</scp>-<i>m</i><i>anno</i>-Heptose and a Mechanistic Study of ADP-<scp>l</scp>-<i>g</i><i>lycero</i>-<scp>d</scp>-<i>m</i><i>anno</i>-Heptose 6-Epimerase
  作者：Jay A. Read、Raef A. Ahmed、Martin E. Tanner

  DOI：10.1021/ol050774q

  日期：2005.6.1

  [GRAPHICS]A chemoenzymatic synthesis of ADP-D-glycero-beta-D-manno-heptose (ADP-D,D-Hep) is described in which D,D-Hep 7-phosphate is converted to ADP-D,D-Hep by two biosynthetic enzymes. This strategy allows access to the 6"-deuterated analogue, which upon incubation with the epimerase showed complete retention of the isotopic label at the 6"-position. This provides evidence for a direct oxidation mechanism in which the hydride initially transferred to the NADP(+) cofactor is subsequently returned to the same carbon in a nonstereospecific manner.